Melanoma-specific memory T cells are functionally active in ret transgenic mice without macroscopic tumors

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9451-9458

  Umansky, Viktor ^a,c   Abschuetz, Oliver ^a   Osen, Wolfram ^a   Ramacher, Marcel ^a   Zhao, Fang ^a   Kato, Masashi ^b   Schadendorf, Dirk ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CHUBU UNIVERSITY   (Japan)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MELANOMA ANTIGEN 2; TYROSINASE RELATED PROTEIN 2;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; INTERFERON PRODUCTION; LYMPH NODE; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TRANSGENIC MOUSE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTRAMOLECULAR OXIDOREDUCTASES; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-RET; T-LYMPHOCYTES;

EID: 56449092100     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1464     Document Type: Article

References (45)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Germeau C, Ma W, Schiavetti F, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005;201:241-8.
3. Arpaia N, Cassano N, Vena GA. Regressing cutaneous malignant melanoma and vitiligo-like depigmentation. Int J Dermatol 2006;45:952-6.
4. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-32.
5. + T-cell memory: known facts, deserted roads, muddy waters, and possible dead ends. Immunol Rev 2006;211:182-96.
6. Prlic M, Williams MA, Bevan MJ. Requirements for CD8 T-cell priming, memory generation and maintenance. Curr Opin Immunol 2007;19:315-9.
7. Feuerer M, Rocha M, Bai L, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001;92:96-105.
8. Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001;7:452-8.
9. Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004;114:67-76.
10. + immune T cells. Cancer Res 1998;58:5439-46.
11. + memory T cells. Cancer Res 2003;63:5582-6.
12. + T cells with potent recall function. J Immunol 2006;177:6730-7.
13. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005;26:360-6.
14. Schmitz-Winnenthal FH, Volk C, Z'graggen K, et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005;65:10079-87.
15. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood 2005;105:2132-4.
16. Müller-Berghaus J, Ehlert K, Ugurel S, et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006;66:5997-6001.
17. Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997;158:3716-20.
18. Feuerer M, Beckhove P, Garbi N, et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003;9:1151-7.
19. Kato M, Takahashi M, Akhand AA, et al. Transgenic mouse model for skin malignant melanoma. Oncogene 1998;17:1885-8.
20. Kato M, Takeda K, Kawamoto Y, et al. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 2004;64:801-6.
21. Houghton A, Polsky D. Focus on melanoma. Cancer Cell 2002;2:275-8.
22. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999;17:380-3.
23. Inaba K, Inaba M, Romani N, et al. 1992. Generation of large numbers of dendritic cells from mouse bone marow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992;176:1693-702.
24. Tsukamoto K, Jackson IJ, Urabe K, Montague PM, Hearing VJ. A second tyrosinase-related protein, TRP-2, is a melanogenic enzyme termed DOPAchrome tautomerase. EMBO J 1992;11:519-26.
25. Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3:269-79.
26. Surh CD, Boyman O, Purton JF, Sprent J. Homeostasis of memory T cells. Immunol Rev 2006;211:154-63.
27. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med 2001;193:741-54.
28. 7, on human leukocytes. J Immunol 1994;153:517-28.
29. + T cells. Immunity 2005;22:259-70.
30. Mahnke YD, Schwendemann J, Beckhove P, Schirrmacher V. Maintenance of long-term tumour-specific Tcell memory by residual dormant tumour cells. Immunology 2005;115:325-36.
31. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005;174:7654-64.
32. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005;174:1269-73.
33. + T cells. Cancer Res 2004;64:1496-501.
34. Lengagne R, Graff-Dubois S, Garcette M, et al. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 2008;180:130-7.
35. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005;353:2654-66.
36. Joncker NT, Marloie MA, Chernysheva A, et al. Antigen-independent accumulation of activated effector/ memory T lymphocytes into human and murine tumors. Int J Cancer 2006;118:1205-14.
37. Zippelius A, Batard P, Rubio-Godoy V, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004;64:2865-73.
38. + T cells infiltrating colorectal tumors identifies a major effector-memory subset with low perforin content. J Clin Immunol 2006;26:447-56.
39. Turk MJ, Guevara-Patiño JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
40. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
41. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006;13:131-45.
42. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
43. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;11:834-46.
44. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
45. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.